Journal des rapports de cas cliniques

Metabolic-Associated Fatty Liver Disease - A Silent or an Aggressive Killer? A Case Report

Abstract

Oana-Bogdana B?rboi, Vasile-Liviu Drug, Alina Ple?a, Diana-Elena Iov, Radu-Alexandru Vulpoi, Ludmila ?tirbu, Mariana Floria and Irina Ciortescu

The rising incidence of hepatocellular carcinoma (HCC) in non-cirrhotic patients in recent years implies the presence of other factors that could contribute to liver carcinogenesis. Metabolic-associated fatty liver disease (MAFLD) can progress to HCC, which poses a significant burden on the healthcare systems worldwide and has a high mortality rate. An aggressive non-invasive surveillance strategy is necessary in order to detect liver cancer in non-cirrhotic patients, especially in those with risk factors such as diabetes, obesity or older age. An acute clinical presentation is possible through complications, such as the development of hemoperitoneum due to the non-traumatic HCC rupture.